

Sid E O'bryant

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7459698/publications.pdf>

Version: 2024-02-01

179
papers

10,879
citations

53794

45
h-index

36028

97
g-index

188
all docs

188
docs citations

188
times ranked

14386
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.8	1,318
2	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	21.4	783
3	Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores. <i>Archives of Neurology</i> , 2008, 65, 1091.	4.5	607
4	Detecting Dementia With the Mini-Mental State Examination in Highly Educated Individuals. <i>Archives of Neurology</i> , 2008, 65, 963-7.	4.5	486
5	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> , 2018, 14, 639-652.	10.1	434
6	Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 821-853.	7.7	370
7	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , 2019, 15, 292-312.	0.8	310
8	The future of blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 115-131.	0.8	250
9	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimer's and Dementia</i> , 2017, 13, 45-58.	0.8	227
10	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	2.6	215
11	Innovative diagnostic tools for early detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 561-578.	0.8	213
12	A Serum Protein-Based Algorithm for the Detection of Alzheimer Disease. <i>Archives of Neurology</i> , 2010, 67, 1077.	4.5	210
13	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015, 11, 549-560.	0.8	205
14	Comparison of the accuracy of kriging and IDW interpolations in estimating groundwater arsenic concentrations in Texas. <i>Environmental Research</i> , 2014, 130, 59-69.	7.5	198
15	Utility of the RBANS in detecting cognitive impairment associated with Alzheimer's disease: Sensitivity, specificity, and positive and negative predictive powers. <i>Archives of Clinical Neuropsychology</i> , 2008, 23, 603-612.	0.5	192
16	Validation of the New Interpretive Guidelines for the Clinical Dementia Rating Scale Sum of Boxes Score in the National Alzheimer's Coordinating Center Database. <i>Archives of Neurology</i> , 2010, 67, 746-9.	4.5	186
17	Assessment of the genetic variance of late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 41, 200.e13-200.e20.	3.1	174
18	Transethnic genome-wide scan identifies novel Alzheimer's disease loci. <i>Alzheimer's and Dementia</i> , 2017, 13, 727-738.	0.8	166

#	ARTICLE	IF	CITATIONS
19	Long-Term Low-Level Arsenic Exposure Is Associated with Poorer Neuropsychological Functioning: A Project FRONTIER Study. <i>International Journal of Environmental Research and Public Health</i> , 2011, 8, 861-874.	2.6	157
20	Developing novel blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 109-114.	0.8	138
21	A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI. <i>PLoS ONE</i> , 2011, 6, e28092.	2.5	126
22	The Arsenic Exposure Hypothesis for Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 311-316.	1.3	99
23	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 965-992.	2.6	96
24	Decreased C-Reactive Protein Levels in Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2010, 23, 49-53.	2.3	92
25	Characterization of Mexican Americans with Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 373-379.	2.6	90
26	Brain-Derived Neurotrophic Factor Levels in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 337-341.	2.6	89
27	Diagnostic Accuracy of the RBANS in Mild Cognitive Impairment: Limitations on Assessing Milder Impairments. <i>Archives of Clinical Neuropsychology</i> , 2010, 25, 429-441.	0.5	85
28	A Blood-Based Algorithm for the Detection of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 55-62.	1.5	84
29	Diagnostic Accuracy of the MMSE in Detecting Probable and Possible Alzheimer's Disease in Ethnically Diverse Highly Educated Individuals: An Analysis of the NACC Database. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2012, 67, 890-896.	3.6	80
30	Risk factors for mild cognitive impairment among Mexican Americans. <i>Alzheimer's and Dementia</i> , 2013, 9, 622.	0.8	79
31	Low-level arsenic exposure, AS3MT gene polymorphism and cardiovascular diseases in rural Texas counties. <i>Environmental Research</i> , 2012, 113, 52-57.	7.5	78
32	Assessing Neuronal and Astrocyte Derived Exosomes From Individuals With Mild Traumatic Brain Injury for Markers of Neurodegeneration and Cytotoxic Activity. <i>Frontiers in Neuroscience</i> , 2019, 13, 1005.	2.8	76
33	Biomarkers in Sporadic and Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 291-317.	2.6	75
34	Biomarkers of Vascular Risk, Systemic Inflammation, and Microvascular Pathology and Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 363-371.	2.6	73
35	Validation of a Serum Screen for Alzheimer's Disease Across Assay Platforms, Species, and Tissues. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 1325-1335.	2.6	73
36	Test of Memory Malingering (Tomm) Trial 1 as a Screening Measure for Insufficient Effort. <i>Clinical Neuropsychologist</i> , 2007, 21, 511-521.	2.3	72

#	ARTICLE	IF	CITATIONS
37	Biomarkers of Alzheimer's Disease Among Mexican Americans. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 841-849.	2.6	69
38	Examining the Test of Memory Malingering Trial 1 and Word Memory Test Immediate Recognition as Screening Tools for Insufficient Effort. <i>Assessment</i> , 2007, 14, 215-222.	3.1	68
39	Estimating the Predictive Value of the Test of Memory Malingering: An Illustrative Example for Clinicians. <i>Clinical Neuropsychologist</i> , 2006, 20, 533-540.	2.3	60
40	Serum Brain-Derived Neurotrophic Factor Levels Are Specifically Associated with Memory Performance among Alzheimer's Disease Cases. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 31-36.	1.5	60
41	A blood screening test for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 83-90.	2.4	54
42	Normative Performance on the Brief Smell Identification Test (BSIT) in a Multi-Ethnic Bilingual Cohort: A Project FRONTIER Study. <i>Clinical Neuropsychologist</i> , 2013, 27, 946-961.	2.3	52
43	Texas Mexican American adult normative studies: Normative data for commonly used clinical neuropsychological measures for English- and Spanish-speakers. <i>Developmental Neuropsychology</i> , 2018, 43, 1-26.	1.4	52
44	Reporting of Demographic Variables in Neuropsychological Research: Trends in the Current Literature. <i>Clinical Neuropsychologist</i> , 2004, 18, 229-233.	2.3	51
45	Clinical Utility of Trial 1 of the Test of Memory Malingering (TOMM). <i>Applied Neuropsychology</i> , 2008, 15, 113-116.	1.5	47
46	Validation of a Latent Variable Representing the Dementing Process. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 639-649.	2.6	45
47	The Link Between C-Reactive Protein and Alzheimer's Disease Among Mexican Americans. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 701-706.	2.6	45
48	Circulating mitochondrial DNA: New indices of type 2 diabetes-related cognitive impairment in Mexican Americans. <i>PLoS ONE</i> , 2019, 14, e0213527.	2.5	45
49	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 27-34.	2.4	44
50	Comorbid Depression and Diabetes as a Risk for Mild Cognitive Impairment and Alzheimer's Disease in Elderly Mexican-Americans. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 129-136.	2.6	42
51	Identifying functional impairment with scores from the repeatable battery for the assessment of neuropsychological status (RBANS). <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 525-530.	2.7	41
52	Diagnostic Validity of Age and Education Corrections for the Mini-Mental State Examination in Older African Americans. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 328-331.	2.6	41
53	Oxidative Stress, Testosterone, and Cognition among Caucasian and Mexican-American Men with and without Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 563-573.	2.6	40
54	Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study. <i>Alzheimer's and Dementia</i> , 2022, 18, 240-250.	0.8	39

#	ARTICLE	IF	CITATIONS
55	Specificity of Malingering Detection Strategies in Older Adults Using the CVLT and WCST. <i>Clinical Neuropsychologist</i> , 2003, 17, 255-262.	2.3	36
56	Hit Rates of Adequate Performance Based on the Test of Memory Malingering (TOMM) Trial 1. <i>Applied Neuropsychology</i> , 2005, 12, 1-4.	1.5	36
57	The Neuropsychology of Recurrent Headache. <i>Headache</i> , 2006, 46, 1364-1376.	3.9	36
58	Implication of common and disease specific variants in CLU, CR1, and PICALM. <i>Neurobiology of Aging</i> , 2012, 33, 1846.e7-1846.e18.	3.1	36
59	A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 97-104.	2.6	36
60	The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12202.	2.4	36
61	The differential impact of depressive symptom clusters on cognition in a rural multi-ethnic cohort: a Project FRONTIER study. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 199-205.	2.7	35
62	The RBANS Effort Index: Base Rates in Geriatric Samples. <i>Applied Neuropsychology</i> , 2011, 18, 11-17.	1.5	35
63	Cognitive differences among depressed and non-depressed MCI participants: a project FRONTIER study. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 377-382.	2.7	35
64	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S171-S191.	2.6	34
65	Utility of the Trail Making Test in the Assessment of Malingering in a Sample of Mild Traumatic Brain Injury Litigants. <i>Clinical Neuropsychologist</i> , 2003, 17, 69-74.	2.3	32
66	The impact of GPX1 on the association of groundwater selenium and depression: a project FRONTIER study. <i>BMC Psychiatry</i> , 2013, 13, 7.	2.6	32
67	A review of symptoms commonly associated with menopause: implications for clinical neuropsychologists and other health care providers. <i>Neuropsychology Review</i> , 2003, 13, 145-152.	4.9	30
68	Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice. <i>Alzheimer's and Dementia</i> , 2023, 19, 36-43.	0.8	30
69	Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 60-72.	2.4	29
70	Neuropsychology of migraine: present status and future directions. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 363-370.	2.8	28
71	Executive Functioning and the Metabolic Syndrome: A Project FRONTIER Study. <i>Archives of Clinical Neuropsychology</i> , 2014, 29, 47-53.	0.5	28
72	Executive functioning mediates the link between other neuropsychological domains and daily functioning: a Project FRONTIER study. <i>International Psychogeriatrics</i> , 2011, 23, 107-113.	1.0	27

#	ARTICLE	IF	CITATIONS
73	Human plasma biomarker responses to inhalational general anaesthesia without surgery. British Journal of Anaesthesia, 2020, 125, 282-290.	3.4	27
74	Low-level groundwater arsenic exposure impacts cognition: a project FRONTIER study. Journal of Environmental Health, 2011, 74, 16-22.	0.5	27
75	Odorant Item Specific Olfactory Identification Deficit May Differentiate Alzheimer Disease From Aging. American Journal of Geriatric Psychiatry, 2018, 26, 835-846.	1.2	26
76	Recursive Support Vector Machine Biomarker Selection for Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 79, 1691-1700.	2.6	26
77	Discrepancies between self-reported years of education and estimated reading level among elderly community-dwelling African-Americans: Analysis of the MOAANS data. Archives of Clinical Neuropsychology, 2007, 22, 327-332.	0.5	24
78	Arsenic exposure, AS3MT polymorphism, and neuropsychological functioning among rural dwelling adults and elders: a cross-sectional study. Environmental Health, 2014, 13, 15.	4.0	23
79	Association Between Cognitive Impairment and Chronic Kidney Disease in Mexican Americans. Journal of the American Geriatrics Society, 2015, 63, 2023-2028.	2.6	23
80	Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics. Neurodegenerative Disease Management, 2016, 6, 203-213.	2.2	23
81	The relationship of CRP and cognition in cognitively normal older Mexican Americans. Medicine (United States), 2019, 98, e15605.	1.0	23
82	Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. Journal of Alzheimer's Disease, 2021, 79, 671-681.	2.6	23
83	An examination of the Boston Naming Test: calculation of an estimated 60-item score from 30- and 15-item scores in a cognitively impaired population. International Journal of Geriatric Psychiatry, 2011, 26, 351-355.	2.7	22
84	A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β -amyloid load in an AD cohort. Scientific Reports, 2017, 7, 14057.	3.3	22
85	Water T2 as an early, global and practical biomarker for metabolic syndrome: an observational cross-sectional study. Journal of Translational Medicine, 2017, 15, 258.	4.4	22
86	A Depressive Endophenotype of Mild Cognitive Impairment and Alzheimer's Disease. PLoS ONE, 2013, 8, e68848.	2.5	22
87	Genome-Wide Methylation of Mild Cognitive Impairment in Mexican Americans Highlights Genes Involved in Synaptic Transport, Alzheimer's Disease-Precursor Phenotypes, and Metabolic Morbidities. Journal of Alzheimer's Disease, 2019, 72, 733-749.	2.6	21
88	A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research. Alzheimer's and Dementia, 2022, 18, 77-87.	0.8	21
89	Discrepancies Between Self-Reported Years of Education and Estimated Reading Level: Potential Implications for Neuropsychologists. Applied Neuropsychology, 2005, 12, 5-11.	1.5	20
90	Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 374-382.	2.4	20

#	ARTICLE	IF	CITATIONS
91	Diagnostic Accuracy of Percent Retention Scores on RBANS Verbal Memory Subtests for the Diagnosis of Alzheimer's Disease and Mild Cognitive Impairment. Archives of Clinical Neuropsychology, 2010, 25, 318-326.	0.5	19
92	Correlations Among the TOMM, Rey-15, and MMPI-2 Validity Scales in a Sample of TBI Litigants. Journal of Forensic Neuropsychology, 2003, 3, 45-53.	0.7	18
93	Depressive Symptom Clusters and Neuropsychological Performance in Mild Alzheimer's and Cognitively Normal Elderly. Depression Research and Treatment, 2011, 2011, 1-6.	1.3	18
94	Regional specific groundwater arsenic levels and neuropsychological functioning: a cross-sectional study. International Journal of Environmental Health Research, 2014, 24, 546-557.	2.7	18
95	A proteomic signature for dementia with Lewy bodies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 270-276.	2.4	18
96	Neurodegeneration from the AT(N) framework is different among Mexican Americans compared to non-Hispanic Whites: A Health & Aging Brain among Latino Elders (HABLE) Study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12267.	2.4	18
97	The Hachinski Ischemic Scale and cognition: the influence of ethnicity. Age and Ageing, 2014, 43, 364-369.	1.6	17
98	The relation of self-report of mood and anxiety to CVLT-C, CVLT, and CVLT-2 in a psychiatric sample. Archives of Clinical Neuropsychology, 2005, 20, 547-553.	0.5	16
99	Normative performance on the executive clock drawing task in a multi-ethnic bilingual cohort: a project FRONTIER study. International Journal of Geriatric Psychiatry, 2012, 27, 959-966.	2.7	16
100	The Link between Potassium and Mild Cognitive Impairment in Mexican-Americans. Dementia and Geriatric Cognitive Disorders Extra, 2018, 8, 151-157.	1.3	16
101	Blood-based biomarkers for Down syndrome and Alzheimer's disease: A systematic review. Developmental Neurobiology, 2019, 79, 699-710.	3.0	16
102	Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer's Symposium. Alzheimer's and Dementia, 2022, 18, 1677-1686.	0.8	16
103	The Utility of the Spatial Span in a Clinical Geriatric Population. Aging, Neuropsychology, and Cognition, 2010, 18, 56-63.	1.3	15
104	The Impact of APOE Status on Relationship of Biomarkers of Vascular Risk and Systemic Inflammation to Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 40, 887-896.	2.6	15
105	Molecular Markers of Amnesic Mild Cognitive Impairment among Mexican Americans. Journal of Alzheimer's Disease, 2015, 49, 221-228.	2.6	15
106	Depression, inflammation, and memory loss among Mexican Americans: analysis of the HABLE cohort. International Psychogeriatrics, 2017, 29, 1693-1699.	1.0	15
107	Blood Biomarkers for Use in Alzheimer Disease—Moving From “How?” to “How?” JAMA Neurology, 2019, 76, 1009.	9.0	15
108	Performance profiles and cut-off scores on the Memory Assessment Scales*1. Archives of Clinical Neuropsychology, 2004, 19, 489-496.	0.5	14

#	ARTICLE	IF	CITATIONS
109	Evolving Relevance of Neuroproteomics in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2017, 1598, 101-115.	0.9	14
110	Biomarkers of Basic Activities of Daily Living in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 429-437.	2.6	13
111	Androgen receptor gene and sex-specific Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2077.e19-2077.e20.	3.1	13
112	Molecular Neuropsychology: Creation of Test-Specific Blood Biomarker Algorithms. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 37, 45-57.	1.5	13
113	Combining Select Neuropsychological Assessment with Blood-Based Biomarkers to Detect Mild Alzheimer's Disease: A Molecular Neuropsychology Approach. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 635-640.	2.6	13
114	Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium's Down Syndrome (ABC-DS) study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12039.	2.4	13
115	A Precision Medicine Approach to Treating Alzheimer's Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 557-568.	2.6	13
116	Can Genetic Analysis of Putative Blood Alzheimer's Disease Biomarkers Lead to Identification of Susceptibility Loci?. <i>PLoS ONE</i> , 2015, 10, e0142360.	2.5	13
117	A brief Spanish-English equivalent version of the Boston Naming Test: A Project FRONTIER Study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 835-845.	1.3	12
118	Texas Mexican American adult normative studies: Normative data for the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). <i>Developmental Neuropsychology</i> , 2018, 43, 27-35.	1.4	12
119	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. <i>Methods in Molecular Biology</i> , 2018, 1750, 139-155.	0.9	12
120	The Influence of Ethnicity on Symbol Digit Modalities Test Performance: An Analysis of a Multi-Ethnic College and Hepatitis C Patient Sample. <i>Applied Neuropsychology</i> , 2007, 14, 183-188.	1.5	11
121	Total Cholesterol and Neuropsychiatric Symptoms in Alzheimer's Disease: The Impact of Total Cholesterol Level and Gender. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 300-309.	1.5	11
122	Introduction to special issue on Advances in blood-based biomarkers of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 110-112.	2.4	11
123	Inflammatory Biomarkers, Depressive Symptoms and Falls Among the elderly in Panama. <i>Current Aging Science</i> , 2019, 11, 236-241.	1.2	11
124	The Four-Point Scoring System for the Clock Drawing Test Does Not Differentiate between Alzheimer's Disease and Vascular Dementia. <i>Psychological Reports</i> , 2010, 106, 941-948.	1.7	10
125	An Empirical Comparison of Competing Factor Structures for the Repeatable Battery for the Assessment of Neuropsychological Status: A Project FRONTIER Study. <i>Archives of Clinical Neuropsychology</i> , 2016, 31, 88-96.	0.5	10
126	The Link between Sleep Disturbance and Depression among Mexican Americans: A Project FRONTIER Study. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 427-431.	2.6	9

#	ARTICLE	IF	CITATIONS
127	A depressive endophenotype of poorer cognition among cognitively healthy community-dwelling adults: results from the Western Australia memory study. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 881-886.	2.7	9
128	Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12023.	2.4	9
129	Relationship of Neurofilament Light (NfL) and Cognitive Performance in a Sample of Mexican Americans with Normal Cognition, Mild Cognitive Impairment and Dementia. <i>Current Alzheimer Research</i> , 2021, 17, 1214-1220.	1.4	9
130	The Influence of Thyroid Function on Cognition in a Sample of Ethnically Diverse, Rural-Dwelling Women: A Project FRONTIER Study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, 219-222.	1.8	8
131	The Relation between Inflammation and Neuropsychological Test Performance. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-6.	2.0	8
132	An item response theory analysis of the Executive Interview and development of the EXIT8: A Project FRONTIER Study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2015, 37, 229-242.	1.3	8
133	Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 24.	6.2	8
134	A Depressive Endophenotype for Predicting Cognitive Decline among Mexican American Adults and Elders. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 201-206.	2.6	8
135	Characteristics of Cognitively Normal Mexican-Americans with Cognitive Complaints. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1485-1492.	2.6	8
136	Vascular Depression and Cognition in Mexican Americans. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 47, 68-78.	1.5	8
137	The Recognition Memory Test Examination of ethnic differences and norm validity. <i>Archives of Clinical Neuropsychology</i> , 2003, 18, 135-143.	0.5	7
138	Using blood markers for Alzheimer disease in clinical practice?. <i>Neurology</i> , 2012, 79, 846-847.	1.1	7
139	Molecular markers of neuropsychological functioning and Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 61-66.	2.4	7
140	IL-7 and Depression: The importance of gender and blood fraction. <i>Behavioural Brain Research</i> , 2016, 315, 147-149.	2.2	7
141	Characterization of Alzheimer's Disease and Mild Cognitive Impairment in Older Adults in Panama. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 897-901.	2.6	7
142	Polypharmacy and Cognition Function Among Rural Adults. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 607-619.	2.6	7
143	Using Fractional Anisotropy Imaging to Detect Mild Cognitive Impairment and Alzheimer's Disease among Mexican Americans and Non-Hispanic Whites: A HABLE Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 266-273.	1.5	7
144	Serum Granulocyte Colony-Stimulating Factor and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 353-360.	1.3	6

#	ARTICLE	IF	CITATIONS
145	Comparison of protein concentrations in serum versus plasma from Alzheimer's patients. <i>Advances in Alzheimer's Disease</i> , 2012, 01, 51-58.	0.9	6
146	Cognition and the Predictive Utility of Three Risk Scores in an Ethnically Diverse Sample. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1049-1059.	2.6	6
147	Cardiovascular Risk Factors, Cognitive Dysfunction, and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2021, 10, 154-162.	1.3	6
148	Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12298.	2.4	6
149	Proteomic Profiles of Neurodegeneration Among Mexican Americans and Non-Hispanic Whites in the HABS-HD Study. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1243-1254.	2.6	6
150	Attenuating Demographic Influences on Verbal Fluency and Animal Naming in a Psychiatric Sample. <i>Applied Neuropsychology</i> , 2004, 11, 208-212.	1.5	5
151	The California Verbal Learning Test-Children's Version: Relation to Factor Indices of the Wechsler Intelligence Scale for Children-Third Edition. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2005, 27, 815-822.	1.3	5
152	Executive Functioning as a Mediator of the Relationship Between Premorbid Verbal Intelligence and Health Risk Behaviors in a Rural-Dwelling Cohort: A Project FRONTIER Study. <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 169-179.	0.5	5
153	Depression and Brain-derived Neurotrophic Factor Levels in Alzheimer's Disease. <i>Neuroscience and Medicine</i> , 2011, 02, 43-47.	0.2	5
154	Metabolic Factors Are Related to Brain Amyloid Among Mexican Americans: A HABS-HD Study. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1745-1750.	2.6	5
155	On Becoming a Peer Reviewer for a Neuropsychology Journal. <i>Archives of Clinical Neuropsychology</i> , 2009, 24, 201-207.	0.5	4
156	Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12033.	2.4	4
157	ApoE Genotype-Dependent Response to Antioxidant and Exercise Interventions on Brain Function. <i>Antioxidants</i> , 2020, 9, 553.	5.1	4
158	Plasma Total Tau and Neurobehavioral Symptoms of Cognitive Decline in Cognitively Normal Older Adults. <i>Frontiers in Psychology</i> , 2021, 12, 774049.	2.1	4
159	Probing the proteome to explore potential correlates of increased Alzheimer's-related cerebrovascular disease in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2022, 18, 1744-1753.	0.8	4
160	Accelerating Hyperparameter Tuning in Machine Learning for Alzheimer's Disease With High Performance Computing. <i>Frontiers in Artificial Intelligence</i> , 2021, 4, 798962.	3.4	4
161	APOE ϵ 4 Genotype Is Related to Brain Amyloid Among Mexican Americans in the HABS-HD Study. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	4
162	The Relation Between Ethnicity and Cognistat Performance in Males Seeking Substance Use Disorder Treatment. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2005, 27, 873-885.	1.3	3

#	ARTICLE	IF	CITATIONS
163	Preliminary Findings on the Cross Cultural Test of Face Recognition. Applied Neuropsychology, 2006, 13, 223-229.	1.5	3
164	O4-11-03: A PROINFLAMMATORY ENDOPHENOTYPE PREDICTS TREATMENT RESPONSE IN A MULTICENTER TRIAL OF NSAIDS IN AD. , 2014, 10, P273-P274.		3
165	F5â€1â€01: PROTEOMIC BIOMARKERS FOR DETECTING AND PREDICTING AD RISKÂAMONG ADULTS WITH DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P1624.	0.8	3
166	Factor structure and measurement invariance of a neuropsychological test battery designed for assessment of cognitive functioning in older Mexican Americans. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 536-544.	2.4	3
167	Combining Select Blood-Based Biomarkers with Neuropsychological Assessment to Detect Mild Cognitive Impairment among Mexican Americans. Journal of Alzheimer's Disease, 2020, 75, 739-750.	2.6	3
168	Acute Regression in Down Syndrome. Brain Sciences, 2021, 11, 1109.	2.3	3
169	Analysis of a precision medicine approach to treating Parkinson's disease: Analysis of the DATATOP study. Parkinsonism and Related Disorders, 2022, 94, 15-21.	2.2	3
170	Psychological symptoms and blood pressure among rural-dwellers. Journal of Health Psychology, 2012, 17, 1203-1211.	2.3	2
171	Bloodâ€based protein predictors of dementia severity as measured by Î±: Replication across biofluids and cohorts. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 763-774.	2.4	2
172	Characterization of the Meal-Stimulated Incretin Response and Relationship With Structural Brain Outcomes in Aging and Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2020, 14, 608862.	2.8	2
173	MRI biomarkers of small vessel disease and cognition: A crossâ€sectional study of a cognitively normal Mexican American cohort. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12236.	2.4	2
174	Levels of Î±-2 Macroglobulin in cognitively normal Mexican- Americans with Subjective Cognitive Decline: A HABLE Study. Current Neurobiology, 2019, 10, 22-25.	1.0	2
175	Vascular risk profile and white matter hyperintensity volume among Mexican Americans and nonâ€Hispanic Whites: The HABLE study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12263.	2.4	2
176	Subjective cognitive complaints and cardiovascular risk factors in older Mexican Americans: A cross-sectional study.. Cerebral Circulation - Cognition and Behavior, 2022, 3, 100126.	0.9	1
177	P3-086: APOE4 GENOTYPE IMPACTS ACCURACY OF BLOOD ALGORITHM FOR DISTINGUISHING MCI FROM AD. , 2014, 10, P659-P660.		0
178	S5-01-02: Blood biomarker assays. , 2015, 11, P302-P302.		0
179	[FTS5â€02â€07]: HEALTH DISPARITIES IN ALZHEIMER'S DISEASE AMONG MEXICAN AMERICANS. Alzheimer's and Dementia, 2017, 13, P1450.	0.8	0